Vorlícek J - Search Results

1

[The importance of autologous transplantation in multiple myeloma].

Pour L, Hájek R, Adam Z, Krejcí M, Vorlícek J. Pour L, et al. Among authors: vorlicek j. Vnitr Lek. 2009 Sep;55(9):767-72. Vnitr Lek. 2009. PMID: 19785373 Review. Czech.

2

Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.

Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, Zahradova L, Buchler T, Vorlicek J, Hajek R. Pour L, et al. Among authors: vorlicek j. Clin Lymphoma Myeloma. 2009 Apr;9(2):151-3. doi: 10.3816/CLM.2009.n.036. Clin Lymphoma Myeloma. 2009. PMID: 19406726

3

Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.

Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J, Hajek R. Pour L, et al. Among authors: vorlicek j. Ann Hematol. 2010 Apr;89(4):385-9. doi: 10.1007/s00277-009-0834-3. Epub 2009 Sep 26. Ann Hematol. 2010. PMID: 19784651

4

Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.

Krejci M, Adam Z, Buchler T, Krivanova A, Pour L, Zahradova L, Holanek M, Sandecka V, Mayer J, Vorlicek J, Hajek R. Krejci M, et al. Among authors: vorlicek j. Ann Hematol. 2010 May;89(5):483-7. doi: 10.1007/s00277-009-0862-z. Epub 2009 Nov 19. Ann Hematol. 2010. PMID: 19924414

5

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R. Krejci M, et al. Among authors: vorlicek j. Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42. doi: 10.3816/CLM.2009.n.086. Clin Lymphoma Myeloma. 2009. PMID: 19951883

6

[Long-term administration of biphosphonates in oncology patients with bone involvement].

Adam Z, Vorlícek J, Tomíska M. Adam Z, et al. Among authors: vorlicek j. Vnitr Lek. 1994 Oct;40(10):671-5. Vnitr Lek. 1994. PMID: 7810088 Czech.

7

[Increased bone density in patients with multiple myeloma treated with clodronate].

Adam Z, Prokes B, Hájek D, Vorlícek J, Tomíska M, Hájek J, Penka M, Mayer J, Hejlová N. Adam Z, et al. Among authors: vorlicek j. Vnitr Lek. 1994 Nov;40(11):726-9. Vnitr Lek. 1994. PMID: 7810097 Czech.

8

[Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].

Adam Z, Elbl L, Vorlícek J, Hájek R, Tomíska M, Hejlová N, Králová E, Novotná H. Adam Z, et al. Among authors: vorlicek j. Vnitr Lek. 1994 Aug;40(8):506-12. Vnitr Lek. 1994. PMID: 7941437 Czech.

9

[Difficulties in the therapy of primary amyloidosis].

Adam Z, Elbl L, Vorlícek J, Králová E, Novotná H, Hájek R, Hejlová N. Adam Z, et al. Among authors: vorlicek j. Vnitr Lek. 1994 Sep;40(9):595-9. Vnitr Lek. 1994. PMID: 7975364 Czech.

10

[Resistance to cytostatic agents in patients with refractory multiple myeloma and possible ways to control it].

Adam Z, Vorlícek J. Adam Z, et al. Among authors: vorlicek j. Vnitr Lek. 1993 Apr;39(4):401-7. Vnitr Lek. 1993. PMID: 8102501 Review. Czech.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters